Author:
Rehab A.A. Alhamashi
Page: 17-26
Published online: 01 Mar 2026
https://doi.org/10.36478/acejrsb.2026. 17.26
Rheumatoid arthritis is a chronic disease of severe impacts on health status due to various physiological disturbances that linked to disease activity and correlate positively with the severity of the disease. Investigation the relationship between the hematological and serum immunological markers with the disease activity in patients with rheumatoid arthritis. Totally, 50 adult male patients diagnosed clinically and biochemically with rheumatoid arthritis in addition to 25 healthy adult males (HC) were subjected to collection of venous blood samples that used for measurement of hematological parameters using the automatic blood analyzer, as well as for obtaining of sera that tested by specific quantitative ELISA kits to measurement of immune markers. According to disease activity, the study patients were divided into low (LDA), moderate (MDA) and high (HDA) categories. In comparison to HC group, the findings of hematology were shown a significant elevation in values of WBCs and neutrophils among all groups of rheumatoid arthritis patients (LDA, MDA, and HDA) while platelets were increased markedly in MDA and HDA groups. In contrast, the findings of RBCs, hemoglobin and hematocrit were reduced significantly among all patients’ groups; whereas, lymphocytes were decreased markedly in MDA and HDA groups. For immunology, the findings of IFN‐a, IL‐6, IL‐8, IL‐10, TNF‐α and TNF‐β were elevated significantly among all groups of study patients; however, elevation in values of IFN‐a, IL‐10, and TNF‐α was more significance in HDA than others; while IL‐8 in MDA, and TNF‐β in LDA and HDA. This study demonstrates a significant association between the hematological and immune markers with the severity of disease suggesting that these markers can serve as valuable, independent biomarkers. Furthermore, the utility of traditional hematological indices in monitoring disease activity undergoing disease‐modifying anti‐rheumatic drug therapy has been established, even when acute‐phase reactants may appear normal. Also, multifaceted nature of disease necessitates a comprehensive understanding of its pathophysiology to develop effective therapeutic strategies that target both articular and extra‐articular manifestations.